Recurrence of hepatocellular carcinoma at the porta-hepatis following liver transplantation diagnosed on EUS-FNA

  • Ronald Samuel
  • Mohammad Bilal
  • Ranjana Nawgiri
  • Shehzad Merwat
  • Sreeram Parupudi
  • Praveen GuturuEmail author
Case Report


Hepatocellular carcinoma (HCC) is a potentially fatal complication of chronic liver disease. Liver transplantation is now the preferred treatment due to good outcomes. We present a unique case of recurrence of HCC at the porta hepatis four years after orthotopic liver transplantation diagnosed via endoscopic ultrasound-guided fine needle aspiration (EUS-FNA). Our report also highlights that intrahepatic recurrence of HCC can be surgically treated. However, further studies are needed to develop treatment algorithms for intra-hepatic recurrence of HCC post liver transplantation.


HCC (hepatic cellular carcinoma) Liver transplant EUS (endoscopic ultrasound) 


Author contributions

RS, MB, RN prepared the manuscript. SM, SP and PG edited the manuscript and provided expert opinion. SP, PG, SM and RN were involved in the care of this case.

Compliance with ethical standards

Conflict of interest

The authors report no conflict of interest related to this manuscript and no financial declaration.

Informed consent

Informed consent was obtained.

Human rights

All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

Informed consent was obtained from all patients for being included in the study.


  1. 1.
    Kneuertz PJ, Cosgrove DP, Cameron AM, et al. Multidisciplinary management of recurrent hepatocellular carcinoma following liver transplantation. J Gastrointest Surg. 2012;16:874–81.CrossRefGoogle Scholar
  2. 2.
    Welker MW, Bechstein WO, Zeuzem S, et al. Recurrent hepatocellular carcinoma after liver transplantation—an emerging clinical challenge. Transpl Int. 2013;26:109–18.CrossRefGoogle Scholar
  3. 3.
    Poon RT, Fan ST, Lo CM, et al. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg. 1999;229:216–22.CrossRefGoogle Scholar
  4. 4.
    Kim HR, Cheon SH, Rha SY, et al. Treatment of recurrent hepatocellular carcinoma after liver transplantation. Asia Pac J Clin Oncol. 2011;7:258–69.CrossRefGoogle Scholar
  5. 5.
    Thomas MB, Jaffe D, Choti MM, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2010;28:3994–4005.CrossRefGoogle Scholar
  6. 6.
    Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.CrossRefGoogle Scholar
  7. 7.
    Sutcliffe R, Maguire D, Portmann B, et al. Selection of patients with hepatocellular carcinoma for liver transplantation. Br J Surg. 2006;93:11–8.CrossRefGoogle Scholar
  8. 8.
    Hollebecque A, Decaens T, Boleslawski E, et al. Natural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantation. Gastroenterol Clin Biol. 2009;33:361–9.CrossRefGoogle Scholar
  9. 9.
    Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl. 2004;10:534–40.CrossRefGoogle Scholar
  10. 10.
    Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Hepatology 2018;68(2):723–750. CrossRefGoogle Scholar
  11. 11.
    Nguyen P, Feng JC, Chang KJ. Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration (FNA) of liver lesions. Gastrointest Endosc. 1999;50:357–61.CrossRefGoogle Scholar
  12. 12.
    Awad SS, Fagan S, Abudayyeh S, et al. Preoperative evaluation of hepatic lesions for the staging of hepatocellular and metastatic liver carcinoma using endoscopic ultrasonography. Am J Surg. 2002;184:601–4 (discussion 604–5).CrossRefGoogle Scholar
  13. 13.
    Fujii-Lau LL, Abu Dayyeh BK, Bruno MJ, et al. EUS-derived criteria for distinguishing benign from malignant metastatic solid hepatic masses. Gastrointest Endosc. 2015;81:1188–96.e1-7.CrossRefGoogle Scholar
  14. 14.
    Saraireh HA, Bilal M, Singh S. Role of endoscopic ultrasound in liver disease: where do we stand in 2017? World J Hepatol. 2017;9:1013–21.CrossRefGoogle Scholar
  15. 15.
    Hammoud GM, Almashhrawi A, Ibdah JA. Usefulness of endoscopic ultrasound-guided fine needle aspiration in the diagnosis of hepatic, gallbladder and biliary tract Lesions. World J Gastrointest Oncol. 2014;6:420–9.CrossRefGoogle Scholar
  16. 16.
    Gleeson FC, Clayton AC, Zhang L, et al. Adequacy of endoscopic ultrasound core needle biopsy specimen of nonmalignant hepatic parenchymal disease. Clin Gastroenterol Hepatol. 2008;6:1437–40.CrossRefGoogle Scholar
  17. 17.
    Dewitt J, McGreevy K, Cummings O, et al. Initial experience with EUS-guided Tru-cut biopsy of benign liver disease. Gastrointest Endosc. 2009;69:535–42.CrossRefGoogle Scholar
  18. 18.
    Edoute Y, Ben-Haim SA, Brenner B, et al. Fatal hemoperitoneum after fine-needle aspiration of a liver metastasis. Am J Gastroenterol. 1992;87:358–60.Google Scholar
  19. 19.
    tenBerge J, Hoffman BJ, Hawes RH, et al. EUS-guided fine needle aspiration of the liver: indications, yield, and safety based on an international survey of 167 cases. Gastrointest Endosc. 2002;55:859–62.CrossRefGoogle Scholar
  20. 20.
    Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321–8.CrossRefGoogle Scholar
  21. 21.
    Rivera L, Giap H, Miller W, et al. Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report. World J Gastroenterol. 2006;12:5729–32.CrossRefGoogle Scholar
  22. 22.
    Mazloom A, Hezel AF, Katz AW. Stereotactic body radiation therapy as a bridge to transplantation and for recurrent disease in the transplanted liver of a patient with hepatocellular carcinoma. Case Rep Oncol. 2014;7:18–22.CrossRefGoogle Scholar
  23. 23.
    Zhou B, Shan H, Zhu KS, et al. Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation. J Vasc Interv Radiol. 2010;21:333–8.CrossRefGoogle Scholar
  24. 24.
    Ko HK, Ko GY, Yoon HK, et al. Tumor response to transcatheter arterial chemoembolization in recurrent hepatocellular carcinoma after living donor liver transplantation. Korean J Radiol. 2007;8:320–7.CrossRefGoogle Scholar
  25. 25.
    Abdo Francis JM. Treatment of non-variceal hemorrhage of the upper digestive tract. Rev Gastroenterol Mex. 1998;63:38–44.Google Scholar
  26. 26.
    Ringe B, Böker K, Schlitt HJ, et al. Recurrence of hepatitis B virus cirrhosis and hepatocellular carcinoma: an indication for retransplantation? Clin Transpl. 1995;9:190–6.Google Scholar
  27. 27.
    de’Angelis N, Landi F, Carra MC, et al. Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic review. World J Gastroenterol. 2015;21:11185–98.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2019

Authors and Affiliations

  1. 1.Department of Internal MedicineUniversity of Texas Medical BranchGalvestonUSA
  2. 2.Division of Gastroenterology and HepatologyUniversity of Texas Medical BranchGalvestonUSA
  3. 3.Department of PathologyUniversity of Texas Medical BranchGalvestonUSA

Personalised recommendations